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Abstract
Background: TEM1/endosialin is an emerging microvascular marker of tumor angiogenesis. We
characterized the expression pattern of TEM1/endosialin in astrocytic and metastatic brain tumors
and investigated its role as a therapeutic target in human endothelial cells and mouse xenograft
models.
Methods: In situ hybridization (ISH), immunohistochemistry (IH) and immunofluorescence (IF)
were used to localize TEM1/endosialin expression in grade II-IV astrocytomas and metastatic brain
tumors on tissue microarrays. Changes in TEM1/endosialin  expression in response to pro-
angiogenic conditions were assessed in human endothelial cells grown in vitro. Intracranial U87MG
glioblastoma (GBM) xenografts were analyzed in nude TEM1/endosialin  knockout (KO) and
wildtype (WT) mice.
Results: TEM1/endosialin was upregulated in primary and metastatic human brain tumors, where
it localized primarily to the tumor vasculature and a subset of tumor stromal cells. Analysis of 275
arrayed grade II-IV astrocytomas demonstrated TEM1/endosialin expression in 79% of tumors.
Robust TEM1/endosialin expression occurred in 31% of glioblastomas (grade IV astroctyomas).
TEM1/endosialin expression was inversely correlated with patient age. TEM1/endosialin showed
limited co-localization with CD31, αSMA and fibronectin in clinical specimens. In vitro, TEM1/
endosialin was upregulated in human endothelial cells cultured in matrigel. Vascular Tem1/endosialin
was induced in intracranial U87MG GBM xenografts grown in mice. Tem1/endosialin KO vs WT
mice demonstrated equivalent survival and tumor growth when implanted with intracranial GBM
xenografts, although Tem1/endosialin KO tumors were significantly more vascular than the WT
counterparts.
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Conclusion: TEM1/endosialin was induced in the vasculature of high-grade brain tumors where its
expression was inversely correlated with patient age. Although lack of TEM1/endosialin did not
suppress growth of intracranial GBM xenografts, it did increase tumor vascularity. The cellular
localization of TEM1/endosialin and its expression profile in primary and metastatic brain tumors
support efforts to therapeutically target this protein, potentially via antibody mediated drug
delivery strategies.
Background
Despite advances in neurosurgical techniques, chemo-
therapeutic regimens and radiotherapy protocols, the
prognosis for patients suffering from malignant astrocy-
toma remains bleak. Novel treatment approaches are
required which attack the unique molecular and biologi-
cal features that contribute to the growth of these tumors.
A particularly promising target is the abnormal tumor vas-
culature, which represents one of the defining characteris-
tics of the most malignant and common astrocytoma,
glioblastoma multiforme (GBM). We previously com-
pared the gene expression profile of endothelial cells iso-
lated from freshly resected GBMs with that of
endothelium isolated from non-neoplastic temporal lobe
[1]. These experiments and subsequent studies identified
21 genes that met the statistical requirements as putative
glioma endothelial markers (GEMS). One especially
promising candidate was TEM1/endosialin.
TEM1 was identified in the tumor endothelium of human
colon carcinoma [2]. Soon after, it was recognized that
TEM1  encoded endosialin, which corresponded to the
tumor vascular endothelial antigen recognized by the FB5
antibody [3,4]. Further analyses revealed selective TEM1/
endosialin expression in tumor endothelium, pericytes and
a subset of fibroblast-like cells of tumor stroma in breast
carcinoma, anaplastic astrocytoma and GBM [5-10].
TEM1/endosialin encodes a transmembrane glycoprotein
and putative membrane receptor. Recent evidence sug-
gests it may interact with extracellular matrix components
including collagen I, collagen IV and fibronection, as well
as Mac-2 BP/90K in promoting vascular migration and
invasion [11,12]. Tem1/endosialin knockout (KO) mice are
fertile and appear to develop normally. However, when
human HCT116 colon carcinoma cells were implanted
orthotopically onto the serosal surface of the large intes-
tine of nude Tem1/endosialin KO mice, both tumor take
and growth were inhibited while the number of tumor
microvessels increased [13]. The selective induction of
TEM1/endosialin in malignant gliomas, its cell surface bio-
availability and the evidence that lack of TEM1/endosialin
can disrupt tumor growth and vascular differentiation in
a xenograft model combine to make it a potential target
for molecular therapy.
We sought to expand these preliminary findings by exam-
ining the specificity of TEM1/endosialin expression in a
larger collection of primary and secondary brain tumors.
We also wished to determine whether TEM1/endosialin
induction in brain tumors was conserved in a commonly
used U87MG intracranial xenograft model. Finally, we
wished to determine whether TEM1/endosialin expression
was required for brain tumor growth in vivo. We confirm
that TEM1/endosialin is induced, primarily in the vascular
compartment, in a wide range of both low-grade and
high-grade cerebral neoplasms and is inversely correlated
with patient age. TEM1/endosialin shows limited co-
localization with fibronectin, a putative binding partner,
in malignant brain tumors. In vitro,  TEM1/endosialin
expression can be stimulated in human microvascular
endothelial cells grown in matrigel. Finally, we show that
Tem1/endosialin upregulation occurs in the tumor vascula-
ture of intracranial GBM xenografts and absence of Tem1/
endosialin is associated with increased numbers of micro-
vessels within tumors explanted from Tem1/endosialin KO
mice, supporting a role for TEM1/endosialin in the migra-
tion and maturation of the brain tumor vasculature. How-
ever, despite its conserved expression pattern in the tumor
cerebrovasculature, we find that Tem1/endosialin  is not
required for intracranial tumor growth in Tem1/endosialin
KO mice.
Methods
Clinical specimens
Clinical specimens were provided by the Brain Tumor
Bank of the University of Pittsburgh as approved by the
University of Pittsburgh Institutional Review Board and
the Neurosurgical Brain Tissue Bank of the University of
Rochester as approved by the University of Rochester
Research Subjects Review Board. All samples were deiden-
tified according to HIPAA regulations prior to being pro-
vided for this research. Astrocytoma array materials were
obtained from surgical patients at Tampere University
Hospital, Tampere, Finland, in 1983-2002, in accordance
with the Research Ethics Committee of Tampere Univer-
sity Hospital.
RNA isolation and reverse transcription
RNA isolations and reverse transcription was performed
as previously described [14]. In brief, total RNA was iso-
lated from 10-30 mg of snap frozen, homogenized tissue
or approximately 106 cultured cells using the Qiagen RNe-
asy Mini Kit (Qiagen, Valencia, CA) according to manu-
facturer's protocol. cDNA was generated using theBMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
Page 3 of 13
(page number not for citation purposes)
SuperScript First-Strand Synthesis System for RT-PCR
(Invitrogen, Carlsbad, CA) according to manufacturer's
protocol.
PCR amplification
All PCR primers were generated by IDT (Integrated DNA
Technologies, Coralville, IA). Sequences available upon
request. PCR reactions were performed using Platinum
Taq Polymerase (Invitrogen) as previously described [14].
Reactions were cycled in a PTC-200 DNA Engine thermal-
cycler (MJ Research, Waltham, MA). Primers for vWF were
used for normalization.
Quantitative RT-PCR amplification
qRT-PCR was carried out on triplicate samples for 40
cycles of 10 s at 95°C, 30 s at 60°C after an initial incuba-
tion at 95°C for 3 min in an Chromo4 thermal cycler
(Bio-Rad, Hercules, CA). Reaction conditions were 1× iQ
SYBR Green super mix (Bio-Rad), 400 nM forward and
reverse primers, and 2.0 μl cDNA in a total reaction vol-
ume of 25 μl. Amplification of vWF was performed for
each cDNA in triplicate for normalization of vascular RNA
content. Primer sequences were: TEM1 (F)5'-ctacgttggt-
ggcttcgagt-3'; TEM1(R)5'-caggcctcgtcttcatcttc-3'; vWF(F)5'-
cacatcgtgacctttgatgg-3'; vWF(R)5'-gtgcttcacctcgatggatt-3'.
Threshold cycle number (Ct) of amplification in each
sample was determined by Bio-Rad software. Relative
mRNA abundance was calculated as the Ct for amplifica-
tion of TEM1/endosialin  minus average Ct  for  vWF,
expressed as a power of 2, i.e. 2-ΔCt. Three individual
TEM1/endosialin values were averaged to obtain mean ±
SD. Statistical significance was determined using a Wil-
coxon rank sum test.
In situ hybridization
Protocol was modified from [14]. Briefly, probe templates
blanketing the target cDNA were generated by PCR ampli-
fication with incorporation of a T7 promoter into the anti-
sense primer. In vitro transcription was performed using
the DIG RNA Labeling Kit (SP6/T7) and T7 RNA polymer-
ase (Roche, Indianapolis, IN) according to manufacturer's
protocol. Sections were deparaffinized in xylenes and
rehydrated in graded ethanols. DIG-labeled RNA probe
cocktails were diluted to 200 ng/ml in RNA hybridization
solution (EMD Bioscience, Madison, WI) and hybridized
to slides overnight at 55°C. Slides were treated with
RNase A/T1 (Ambion, Austin, TX) and stringently washed.
Slides were blocked with normal rabbit IgG (Dako)
diluted 1:20 in buffer (100 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% casein). For detection, sections were incubated
with rabbit HRP-anti-DIG primary (Dako) diluted 1:150
in blocking buffer. Signal was amplified by incubating
each slide with one drop of biotinyl-tyramide (Dako).
Slides were washed then incubated in goat HRP-anti-
biotin secondary (1:100, Vector Laboratories, Burlingame,
CA) in blocking buffer. Amplification with biotinyl-tyra-
mide was repeated. Sections were incubated with goat AP-
anti-biotin tertiary (1:100, Vector) in blocking buffer and
washed. Signal was detected by staining with Fast Red
(Sigma-Aldrich, St. Louis, MO) followed by counterstain-
ing with Probe/Hematoxylin counterstain (Biomeda, Fos-
ter City, CA). Slides were mounted with Crystal/Mount
(Biomeda). Images were captured with an Olympus BH-2
microscope using Spot Insight Color model 3.2.0 camera
and Spot Advanced software (Diagnostic Instruments,
Sterling Heights, MI).
Antibodies
TEM1/33, an affinity purified rabbit polyclonal antibody
to human TEM1/endosialin, was raised against the pep-
tide RLGFRPAEDDPHRCVDT (Quality Controlled Bio-
chemicals, Hopkinton, MA). Additional goat anti-TEM1/
endosialin antibodies sc-48097 and sc-48098 were from
Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit-anti-
vWF (ab6994) was from Abcam (Cambridge, MA). Goat
anti-rabbit-HRP secondary antibody was from Jackson
ImmunoResearch Laboratories (West Grove, PA). For
immunofluorescence, mouse anti-alpha smooth muscle
actin (αSMA) (Sigma), mouse anti-CD31 (Zymed, San
Francisco, CA) and mouse anti-fibronectin (FN) (Sigma)
were used. Secondary antibodies for immunofluorescence
included anti-rabbit Alexa Fluor 568 (red) and anti-goat
Alexa Fluor 488 (green) (Invitrogen).
Immunohistochemistry
Sections were deparaffinized in xylenes and rehydrated in
graded ethanols. Slides were washed in 1× PBS and then
quenched with 0.3% H202 in 0.3% normal serum/1× PBS
for 5 minutes. Slides were washed in 1× PBS and blocked
with 4% normal goat serum 1×PBS. Sections were
exposed to rabbit polyclonal anti-TEM1 (1:50) or anti-
vWF (1:500) at 4°C overnight. Sections were washed with
1× PBS and exposed for 1 hour to goat-anti-rabbit second-
ary, diluted 1:300. Sections were washed in 1× PBS then
exposed to Vectastain-Elite ABC (Vector) for 30 minutes.
Sections were washed in 1× PBS and incubated with
NovaRed substrate (Vector). Slides were rinsed with dis-
tilled water and counterstained with Mayer's Hematoxylin
(Biomeda, Foster City, CA). Sections were rinsed with dis-
tilled water, exposed to 0.08% NH4OH for 3 minutes,
rinsed with distilled water and mounted with Crystal/
Mount. Images were captured as described above.
Astrocytoma array
Tumor specimens were fixed in 4% phosphate-buffered
formaldehyde and processed into paraffin embedded tis-
sue microarrays as previously described [15]. 275 samples
were included in the analyses: 39 grade II, 41 grade III,
and 195 grade IV. Patient age ranged from 3 to 80 years
(mean ± SD: 50.4 ± 15.2). TEM1/endosialin expression wasBMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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assessed by in situ hybridization as described above. Sta-
tistical analyses, including Mann-Whitney and Kruskal-
Wallis tests to correlate expression to age, were performed
using SPSS 11.0 for Windows (SPSS, Chicago, IL).
Immunofluorescence
Slides were deparaffinzed in xylenes and rehydrated in
graded ethanols and rinsed in dH2O as described above.
For TEM1/CD31, slides were boiled for 15 minutes in cit-
rate buffer (Zymed), cooled for 20 minutes, then washed
in PBS for 5 minutes. TEM1/αSMA staining did not
require antigen retrieval. For TEM1/FN staining, slides
were incubated with 0.1% proteinase K at 37°C for 15
minutes. Slides were washed in PBS and the blocked with
5% normal donkey serum containing 3% BSA in PBS for
30 minutes. Slides were incubated with primary antibod-
ies diluted 1:10 (TEM1/33), 1:20 (CD31), 1:50 (αSMA) or
1:100 (FN) in blocking buffer at 37° for 1 hour. Slides
were then rinsed with PBS and incubated with the appro-
priate secondary in diluted 1:200 in normal host serum
for 1 hour at 37°C in the dark. Slides were rinsed in PBS
before the addition of ToPro3 nuclear stain (Invitrogen)
and then mounted with Prolong Gold mounting media
(Invitrogen). Confocal images were captured using Zeiss
LSM 510 Axioskop 2 microscope (Zeiss Microimaging,
Thornwood, NY) and analyzed with Zen 2007 software
(Zeiss).
Cell lines and culture conditions
Human primary brain microvascular endothelial cells
(HPBMEC) (Cell Systems, Kirkland, WA) were main-
tained in CSC-Complete media (Cell Systems). Human
dermal microvascular endothelial cells (HMVEC) (Lonza,
Walkersville, MD) were maintained in EBM/EGM-2MV
growth media with 1× growth supplements (hEGF, hydro-
cortisone, GA-1000, FBS, VEGF, hFGF-B, R3-IGF-1, and
ascorbic acid) (Cambrex). U87MG tumor cells (ATCC,
Manassas, VA) were maintained in Minimum Essential
Medium Eagle with Earle's Salts and L-glutamine (Invitro-
gen, Carlsbad, CA), supplemented with 10% FBS, 0.1 mM
MEM non-essential amino acids, 0.1 mM MEM sodium
pyruvate, sodium bicarbonate, 1 unit/ml penicillin, and 1
μg/ml streptomycin (Invitrogen). Cells were maintained
in a 5% CO2 atmosphere at 37°C. Endothelial cells were
used at passage 3-7 in all experiments. For growth factor
experiments, endothelial cells were cultured in the pres-
ence of 25 ng/ml VEGF (Sigma), 10 ng/ml TGFβ(R&D Sys-
tems), 100 ng/ml IGF-1 (Upstate, Billerica, MA), 50 ng/ml
SDF-1 (Biosource, Carlsbad, CA), 20 ng/ml SCF (Bio-
source) or 50 ng/ml SF/HGF (Biosource) for 48 hours
prior to harvest and RNA isolation. Culture of endothelial
cells in matrigel (BD Bioscience, Bedford, MA) was per-
formed as described [14]. Cells were harvested from
matrigel using Cell Recovery Solution (BD Bioscience)
according to manufacturer's protocol. In brief, the cell/
matrigel layer was transferred to a 50 ml tube and 4 ml of
Cell Recovery Solution was added. The mixture was incu-
bated on ice to completely dissociate the matrigel and
release the cells, which were then collected by centrifuga-
tion, washed twice in PBS and used for RNA isolation.
Intracranial xenografts
U87MG cells were harvested with trypsin (Invitrogen) and
resuspended at a concentration of 105 cells/10 μl antibi-
otic-free DMEM. Athymic nu/nu mice were purchased
from the National Cancer Institute (Frederick, MD) and
the nude Tem1/endosialin KO and WT mice were derived as
previously described [13]. Mice were anesthetized using
an intraperitoneal injection of 3 ml/kg xylazine/ketamine
and tumor cells were stereotactically injected as previously
described [16]. Mice were observed daily and survival
time was recorded. Mice were euthanized by barbituate
overdose when they exhibited symptoms of tumor burden
or distress. Brains were surgically removed, formalin fixed
and embedded in paraffin. All procedures were approved
by the Institutional Animal Care and Usage Committees
of the Johns Hopkins University School of Medicine and
the University of Rochester.
Vessel counts
Tumor sections were immunostained for vWF, as
described above. Vessels were counted in 10 non-overlap-
ping, 400× fields (5 fields each from two anatomically dis-
tinct tumor regions), in 6 Tem1/endosialin WT and 6 Tem1/
endosialin  KO xenograft tumors. Statistical significance
was determined by Wilcoxon rank sum test.
Results
TEM1/endosialin is upregulated in both primary and 
secondary brain tumors
Our previous SAGE data and studies from others indi-
cated that TEM1/endosialin was upregulated in the micro-
vasculature of human GBMs and a subset of brain tumors
[1,5,7]. In order to confirm that TEM1/endosialin induc-
tion was common to both primary and secondary brain
tumors, we performed quantitative RT-PCR using TEM1/
endosialin specific primers on mRNA isolated from frozen
clinical specimens of 2 non-neoplastic brain tissues and 5
GBMs, as well as 5 specimens of metastatic lung adenocar-
cinoma resected from brain. Reactions were normalized
to vWF in order to account for the increased vascularity of
the tumor specimens. Representative standard RT-PCR
data are shown in Fig 1A. Quantitative RT-PCR results
confirmed that upregulation of TEM1/endosialin is detect-
able in whole tissue from both primary and secondary
brain tumor samples as compared to non-neoplastic con-
trols and support a role for TEM1/endosialin as an ang-
iogenic marker for CNS neoplasia (Fig 1B).
We next used in situ hybridization and immunohisto-
chemistry to localize expression of TEM1/endosialin
mRNA and protein (Fig 1C) using an independent array ofBMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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7 non-neoplastic (reactive) brain tissue specimens, 4 pilo-
cytic astrocytomas, 7 metastatic adenocarcinomas (3 lung
adenocarcinomas, 1 lung adenosquamous carcinoma, 1
non-small cell lung carcinoma, 1 esophageal adenocarci-
noma and 1 colon adenocarcinoma) and 9 GBMs. TEM1/
endosialin expression was detected in the vasculature of
both GBMs and metastatic brain tumors, as compared to
the endothelial control marker, vWF. In GBMs, 3/9
tumors or approximately 33% of the tissues demonstrated
a robust staining pattern for TEM1/endosialin  (nearly
100% of vessels positive), while another 2/9 tumors
showed moderate expression (approximately 50% of ves-
sels positive) (Table 1). Similarly, 2/7 metastatic tumors
(28%) showed robust staining for TEM1/endosialin while
another 2/7 (28%) demonstrated a moderate staining pat-
tern. TEM1/endosialin expression was occasionally noted
in a subset of tumor stromal cells. Little to no staining was
detected in reactive (non-neoplastic) brain tissue. Thus,
high-grade primary and secondary brain tumors show
similar expression profiles for TEM1/endosialin. These
numbers are consistent with previous work [7], and sug-
gest that the role of TEM1/endosialin is critical for vessel
development in the brain, regardless of the tumor tissue
of origin. Interestingly, 1 of 4 pilocytic astrocytoma speci-
Localization of TEM1/endosialin expression Figure 1
Localization of TEM1/endosialin expression. A. Representative RT-PCR for TEM1/endosialin (TEM1) in whole cell lysates 
from two GBMs (T1, T2), two metastatic brain tumors (T3, T4) and two non-neoplastic controls (N1, N2). Expression was 
normalized to von Willebrand Factor (vWF), an endothelial positive control. B. Combined quantitative RT-PCR results for 
TEM1/endosialin in two controls (N), five GBMs (GBM) and five metastatic tumors (Met). Error bars, standard error of the 
mean. *p = 0.05. C. TEM1/endosialin was visualized by immunohistochemistry (IHC) using the TEM1/33 custom antibody or in 
situ hybridization (ISH) in glioblastoma (GBM), metastatic brain tumor (MET) and non-neoplastic brain tissues (Normal). Stain-
ing for vWF was used as an endothelial positive control. Original magnification for whole spot, 40×; detail, 100×.
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mens showed robust TEM1/endosialin  expression while
the remaining 3 had little to no TEM1/endosialin reactivity.
Pilocytic astrocytomas are low-grade astrocytomas, but
can be highly angiogenic and often demonstrate enhance-
ment and blood-brain barrier disruption on MRI scans.
As astrocytomas account for more than half of primary
CNS malignancies, we expanded our examination to a
larger group of primary astrocytic brain tumors in order to
look for associations between TEM1/endosialin expression
and clinically relevant pathologic features. We used in situ
hybridization to probe expression of 275 arrayed grade II-
grade IV astrocytic tumors. The results are summarized in
Table 2. Overall, TEM1/endosialin expression was detected
in 79% of tumor samples (Table 2). When we focused on
the grade IV astrocytomas (GBMs) alone, which constitute
the most aggressive and lethal subtype, 31% of the tumors
demonstrated moderate to strong staining for TEM1/endo-
sialin (Table 2). These data confirm that TEM1/endosialin
is widely expressed in astrocytic tumors. TEM1/endosialin
expression in grade II-IV astrocytomas demonstrated a sta-
tistically significant inverse correlation with patient age (p
= 0.004) (Table 2), although it showed no correlation
with other common measures such as tumor proliferation
index (MIB-1) or apoptotic rate.
Co-localization of TEM1/endosialin and fibronectin
Fibronectin (FN), collagen I and collagen IV were recently
identified as potential binding partners for TEM1/endo-
sialin [11]. We therefore stained the same GBM/metastatic
brain tumor tissue array for FN to see if there was a corre-
lation between TEM1/endosialin and FN expression pat-
terns. TEM1/endosialin and FN were co-upregulated in
some tumors, although the correlation was not consistent
(Table 1). A similar pattern of upregulation was noted for
collagen I and collagen IV (YL, unpublished data). Using
immunofluorescence, we detected limited co-localization
of TEM1/endosialin and FN in GBM and metastatic brain
tumor sections, suggesting that physiologic interactions
between TEM1/endosialin and FN may occur, but that
such interactions are not extensive in clinical settings of
CNS neoplasia (Fig 2 and Additional file 1). Similar
results were obtained using a custom synthesized, affinity
purified anti-TEM1 antibody or commercial antibodies,
targeting 3 different epitopes within the protein.
Regulation of TEM1/endosialin expression in vitro
TEM1/endosialin  was originally characterized as an
endothelial cell marker, although recent studies have pro-
vided evidence for its expression in endothelial progenitor
cells, mesenchymal stem cells, tumor pericytes, all of
which contribute to the tumor vasculature, and a subpop-
ulation of tumor stromal cells [8,10,17-20]. Co-immun-
ofluorescence for TEM1/endosialin and the pericyte
marker alpha-smooth muscle actin (αSMA) in the micro-
vasculature of our GBMs and metastatic brain tumors
revealed minimal overlap of the two proteins at the cellu-
lar level, although the markers did routinely track along
the same vessels (Fig 2). Co-immunofluorescence for
TEM1/endosialin and CD31, an endothelial marker, also
demonstrated limited co-localization of the two proteins,
although again both proteins were found on shared ves-
sels (Fig 2). Our results differ in degree slightly from those
of Simonavicius, et al. [5], but this may be due to differ-
ences in antibodies, tissue fixation conditions (Rouleau et
al. experienced significantly different TEM1/endosialin
staining results from FFPE versus frozen tumor tissues
[21]) or clinical tumor heterogeneity.
We wished to determine factors that may induce TEM1/
endosialin in the endothelium of human brain tumors in
order to further clarify the role of this protein. Little or no
Tem1/endosialin induction was detected in human micro-
vascular endothelial cells (HMVECs) or human brain
microvascular endothelial cells (HBMECs) after exposure
Table 1: TEM1/endosialin and fibronectin expression levels in 
brain tissue microarray.
Tissue Sample TEM1 FN
Control 1 - +
2- +
3- +
4- + +
5+ / - +
6+ +
7+ / - + +
PA 1 +++ +++
2+ +
3+ +
4- + +
Met 1 +++ +++
2 + +++
3+ + + +
4+ + +
5 +++ ++
6+ + + +
7+ + +
GBM 1 + +
2+ + + +
3+ / + + + +
4 + +/++
5 +++ +
6+ + +
7+ +
8 +++ +++
9 +++ ++
NOTE: Non-neoplastic control tissue (Control), pilocytic astrocytoma 
(PA), metastatic brain tumors (Mets) and glioblastoma (GBM). TEM1/
33 and mouse anti-fibronectin antibodies were used. (-) no staining; 
(+) weak staining or 10% vessels; (++) moderate staining or 
approximately 50% of vessels; and (+++) strong staining or nearly 
100% of vessels.BMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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to pro-angiogenic growth factors, including vascular
endothelial growth factor (VEGF), transforming growth
factor beta (TGF-β), insulin-like growth factor 1 (IGF1),
stem cell factor (SCF), stromal cell-derived factor 1 (SDF-
1) and scatter factor/hepatocyte growth factor (SF/HGF)
(Fig 3A). Likewise, culturing primary endothelial cells
under hypoxic conditions (2% oxygen for 24 hours) did
not induce TEM1/endosialin expression (YL, unpublished
data). Since it has been proposed that TEM1/endosialin
may interact with proteins within the extracellular matrix
as well as tumor stromal cells to promote vascular inva-
sion and migration [11], we examined the effects of
growth in matrigel on TEM1/endosialin  expression in
HMVEC cells. After 6 hours in matrigel, cells were har-
vested and TEM1/endosialin  expression was assessed by
quantitative RT-PCR using human specific primers.
HMVEC cells cultured in matrigel induced TEM1/endosia-
lin ten-fold compared to HMVEC cells cultured on plastic
(Fig 3B). No expression was detected in reverse tran-
scriptase negative samples or in matrigel-only control iso-
lates. This suggests that microvascular endothelial cells
can induce TEM1/endosialin when exposed to a complex
extracellular environment.
TEM1/endosialin is induced in intracranial GBM 
xenografts
Previous studies demonstrated robust TEM1/endosialin
induction in B16 melanoma and HCT116 colon carci-
noma xenografts grown in mice, while very low levels of
TEM1/endosialin expression were reported in normal adult
mouse brain [9]. We therefore sought to determine
whether induction of TEM1/endosialin was conserved in
an intracranial GBM xenograft model. Human U87MG
glioblastoma cells were implanted intracranially into ath-
ymic nude mice. In situ hybridization using mouse spe-
cific riboprobes was used to measure mouse TEM1/
endosialin  expression in the subsequently harvested
tumors. The results demonstrated mouse TEM1/endosialin
induction in the vasculature of the tumor, but not in the
surrounding normal mouse brain (Fig 4A). Staining for
TEM1/endosialin was often concentrated near the margin
of the tumor, although this observation did not reach sta-
tistical significance, a characteristic noted in human brain
tumors as well (BNW, unpublished data).
Tem1/endosialin expression is not required for brain tumor 
growth in vivo
In order to investigate whether induction of Tem1/endosia-
lin is required for tumorigenesis and/or angiogenesis in
brain tumors, we injected U87MG human GBM cells
intracranially into nude Tem1/endosialin KO and WT mice.
No significant difference in survival time between the
Tem1/endosialin  KO and WT animals was detected (Fig
4B). Neither was there a detectable difference in tumor
take or volume. We were able to detect Tem1/endosialin in
the vasculature of the WT, but not the KO, tumors, con-
firming the genotype of the mice.
Since  TEM1/endosialin  expression has been noted in
tumor stromal cells, as well as vascular and perivascular
cells, we screened the Tem1/endosialin KO and WT tumors
for expression of human TEM1/endosialin. We did not
detect appreciable TEM1/endosialin  staining by in situ
hybridization in the tumor stroma of either the knockout
or wildtype xenografts. This suggests that growth of the
intracranial xenografts was not supplemented by TEM1/
endosialin expression from the U87MG tumor cells them-
selves.
Nanda, et al., reported increased numbers of microvessels
in xenografted colon carcinomas grown in the intestine of
nude Tem1/endosialin knockout mice as compared to their
wildtype counterparts [13]. We therefore examined the
intracranial U87MG xenografts for a similar phenotype.
Table 2: Expression of TEM1/endosialin in grade II-IV astrocytoma microarray.
Tumor Negative Positive Total
Grade II 7 32 39
Grade III 8 33 41
GBM 42 153 195
Total 57 218 275
Tumor Negative Weak Mod/Strong
GBM 42 91 62
TEM1 Neg/Weak
(N = 156)
TEM1 Mod/Strong (N = 93)
Age (years)
Mean 54.8 49.1
Median 57.2 50.5
SD 15.2 15.5
NOTE: Positive staining as measured by ISH was defined as: weak or 10% of vessels; moderate or approximately 50% of vessels; and strong or nearly 
100% of vessels. TEM1/endosialin expression inversely correlated with patient age in grade II-IV astrocytomas for which age data was available, p = 
0.004, Mann-Whitney test. SD: standard deviation.BMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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The tumors from the Tem1/endosialin  KO animals had
approximately 40% more vessels than the tumors grown
in the wildtype mice (Fig. 4C, D). This suggests that
although GBM xenografts grew normally in the Tem1/
endosialin knockout animals, tumor angiogenesis was nev-
ertheless altered. Staining with antibodies to αSMA did
not demonstrate any difference in pericyte coverage
between the WT and KO tumor vessels (MCW, unpub-
lished data). So while Tem1/endosialin is not required for
overall growth of this intracranial brain tumor model, it
does appear to be required for normal development of the
tumor cerebrovasculature, although the mechanism for
this remains unclear.
Discussion
TEM1/endosialin/CD248  encodes a 165 kD single-pass
transmembrane glycoprotein. It is a C-lectin type receptor
with homology to thrombomodulin. Several studies iden-
tified TEM1/endosialin as a marker of tumor endothelium
and isolated activated fibroblasts within the tumor stroma
[7,9]. Little to no expression of TEM1/endosialin was noted
in normal adult tissues. Alternate studies have argued that
TEM1/endosialin in the tumor vasculature is expressed by
vessel-associated pericytes [8,10,19]. Two additional
reports identified TEM1/endosialin in populations of
VEGFR2+/CD31+/CD45-/VE-cadherin+  endothelial pre-
cursor cells derived from CD133+/CD34+  cells or in
CD45+/VE-cadherin+ "vascular leukocytes" [20,22]. Both
cell types have been proposed to contribute to tumor vas-
cularization, although the degree to which either one
incorporates into tumor vessels remains controversial.
Human umbilical vein endothelial cells immortalized
with SV40 large/small T-antigen, a model of proliferating
neovascular endothelial cells, also express TEM1/endosia-
lin [23]. We argue that TEM1/endosialin is expressed to var-
ying degrees by tumor endothelial cells, pericytes and
stromal fibroblasts. In normal blood vessels, the pericytes
bind tightly to endothelial cells and influence migration,
stabilization and maturation of the endothelium. In the
cerebrovasculature, pericytes are additionally critical for
maintenance of the differentiated blood-brain barrier
(BBB) and failure of the BBB in brain tumors is associated
with disruption and loss of pericytes lining endothelial
cells. Pericytes are of emerging interest as therapeutic tar-
gets as vessels may be more sensitive to chemotherapy or
radiotherapy when denuded of pericytes. When Bergers, et
al., targeted both the endothelial cell and pericyte com-
partments with combinatorial receptor tyrosine kinase
inhibitory (RTKI) therapies, they achieved more favorable
responses than with either therapy alone [24]. Cao, et al.,
demonstrated that systemic overexpression of Ang2
blocked pericyte recruitment to tumor vessels and led to
massive vascular destabilization and tumor suppression
[25]. The collective data support the hypothesis that
TEM1/endosialin has a favorable expression profile for tar-
geting both the endothelial and pericytic portions of the
tumor vasculature.
Expression of TEM1/endosialin by a subset of tumor
fibroblasts may also influence tumor growth and angio-
genesis. Activated tumor fibroblasts contribute to the dep-
osition of fibronectin, collagen I and collagen IV, all of
which may bind TEM1/endosialin and guide vessel inva-
sion, migration or differentiation. SDF-1 expression by
activated tumor fibroblasts has been shown to drive
tumor progression and angiogenesis in breast carcinoma
models and has been reported to recruit endothelial pro-
genitor cells to the microvasculature of murine gliomas,
where differentiation into both pericytes and endothe-
lium was detected [26,27]. A recent genetic study reported
that TGFβ1 treatment of proliferating endothelial cells led
to an endothelial-mesenchymal transition, wherein
endothelial cells downregulated CD31 and upregulated
fibroblast-specific protein-1 (FSP-1). They confirmed the
presence of FSP1+/CD31+  intermediate cells in tumor
models [28]. Further work is necessary to fully determine
the complete expression profile of TEM1/endosialin and its
relationship to these intricately related stromal cell popu-
lations.
In the US, primary brain tumors are diagnosed in approx-
imately 40,000 new patients a year. In addition, brain
metastases occur in 20-40% of cancer patients, leading to
200,000-400,000 new cases of brain metastases a year.
Despite differences in the molecular fingerprints of the
tumor cells themselves, it may be possible to identify
Immunofluorescence for TEM1/endosialin: co-localization in  tumor specimens Figure 2
Immunofluorescence for TEM1/endosialin: co-locali-
zation in tumor specimens. TEM1 and CD31 (top panel), 
αSMA (middle panel) and fibronectin (FN, bottom panel) co-
localize to microvessels in human GBMs, but demonstrate 
limited cellular overlap. Anti-TEM1 (TEM1/33), red. Anti-
CD31, anti-αSMA and anti-FN, green. Nuclei, blue. Scale bar, 
20 μm.
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TEM1
TEM1
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Expression of TEM1/endosialin by cultured endothelial cells Figure 3
Expression of TEM1/endosialin by cultured endothelial cells. A. Expression of TEM1/endosialin after treatment of 
endothelial cells with pro-angiogenic growth factors. Cells were treated for 48 hours (see Methods) and analyzed by quantita-
tive RT-PCR. Error bars, standard error of the mean. No significant change in TEM1/endosialin was detected. B. Induction of 
TEM1/endosialin after growth of endothelial cells in matrigel. Cells were grown on plastic (Control) or in matrigel (Matrigel) for 
6 hours then analyzed by quantitative RT-PCR. Error bars, standard error of the mean. *p = 0.05. After 6 hours on matrigel 
and prior to harvest, HMVEC cells demonstrate branching tubulogenesis (lower right) while cells grown on plastic do not 
(lower left).BMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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common changes in the vasculature of these disparate
tumor types. Initial studies by ourselves and others
reported TEM1/endosialin  upregulation in human brain
tumors [1,5,7]. We wanted to expand these findings in
order to better establish the full extent of TEM1/endosialin
expression in brain tumors. This study confirms expres-
sion of TEM1/endosialin at the RNA and protein level in
astrocytic and metastatic brain tumors, with little to no
expression in normal control brain. Expression was pri-
marily limited to the tumor vasculature but occasional
Tem1/endosialin expression in mouse brain tumor models Figure 4
Tem1/endosialin expression in mouse brain tumor models. A. Induction of Tem1/endosialin in intracranial U87MG 
xenografts grown in nude mice. ISH with mouse specific riboprobes detected Tem1/endosialin (Tem1) in tumor (T) but not nor-
mal mouse brain (NL). Probes for mouse vWF were used as a positive endothelial control (vWF). Original magnification, 200×. 
B. Survival of nude TEM1/endosialin WT and KO mice after intracranial injection with 105 U87MG glioblastoma cells. Animals 
sacrificed after 100 days showed no evidence of tumor take. C. Tumor vessels stained for vWF in intracranial xenografts from 
nude TEM1/endosialin WT or KO mice. Size bar, 50 μm. D. Comparison of vessel numbers from nude TEM1/endosialin WT and 
KO tumors. Ten non-overlapping high power fields were counted per animal. Error bars, standard error of the mean. *p = 
0.001.
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stromal cells also stained for TEM1/endosialin. Greater
than 30% of GBMs displayed robust TEM1/endosialin
expression, while lesser percentages of lower grade tumors
expressed  TEM1/endosialin. Unfortunately, we did not
know whether the individual specimens analyzed were
from the tumor center or closer to the tumor margin. Pre-
liminary mouse xenograft data suggested that Tem1/
endosialin staining was increased along the tumor mar-
gin, but this needs to be further investigated in both clin-
ical and mouse tumors. It will be especially useful to
assess Tem1/endosialin  expression in future experiments
using xenografted primary glioma spheroids or glioma
stem cells, which grow as a more highly invasive intracra-
nial tumor than the U87 model, although with less pro-
nounced angiogenesis. Interestingly, one pilocytic
astrocytoma displayed robust expression of TEM1/endosia-
lin. Although pilocytic astrocytomas are considered low-
grade tumors, they are highly angiogenic and often
enhance on MRI, which is indicative of vascular leakiness,
disruption of the blood-brain barrier and often more
aggressive disease. A recent study in breast cancer identi-
fied an association between TEM1/endosialin expression
and progressive and/or recurrent disease as well as nodal
involvement, all hallmarks of a more aggressive disease
state [6]. Thus, TEM1/endosialin may have prognostic
value for breast cancer. We did detect a statistically signif-
icant (p = 0.004) inverse correlation between TEM1/endo-
sialin  expression in astrocytomas and patient age,
although the implications of this remain unclear. While
diagnosis at a younger age can be a predictor of long-term
survival for GBM [29], our initial analyses reveal no differ-
ence in survival between TEM1/endosialin expressing and
non-expressing tumors.
Tomkowicz, et al. recently identified collagen types I and
IV and fibronectin as potential ligands for TEM1/endosia-
lin [11]. They showed that CHO cells engineered to over-
express TEM1/endosialin (CHO-TEM1) exhibited greater
adhesion to fibronectin than control CHO cells (CHO-
K1). They suggested a model by which TEM1/endosialin
is induced in cells associated with endothelium and stro-
mal fibroblasts. The subsequent interactions between
TEM1/endosialin expressing cells and fibronectin, colla-
gen I or IV present in the extracellular matrix drive cellular
migration required for tumor invasion and angiogenesis.
In an independent study, TEM1/endosialin and collagen
IV were shown to colocalize in finger-like processes dur-
ing angiogenic development in the human fetal telen-
cephalon [30]. We had identified collagen I and collagen
IV as putative glioma endothelial markers which exhib-
ited a minimum 4-fold induction as compared to normal
endothelial cell samples and were induced in both glioma
and colon carcinoma endothelium [1]. Therefore, we were
curious to determine whether we could detect co-localiza-
tion of fibronectin with TEM1/endosialin in our primary
and secondary tumor samples. We did detect upregulation
of both TEM1/endosialin and fibronectin within the same
tumor specimens, although only a subset of the samples
showed co-localization along the vasculature, supporting
a physiologic interaction of these proteins. In addition,
Tomkowicz and colleagues showed that the CHO-TEM1
cells, but not CHO-K1 control cells, grew with web-like
morphology and formed large clusters when cultured in
matrigel. The CHO-TEM1 cells also exhibited enhanced
migration through matrigel that was blocked by incuba-
tion with a humanized antibody targeted against TEM1/
endosialin [11]. Others have shown that incubation with
anti-TEM1/endosialin antibodies can block tube forma-
tion by endothelial progenitor cells and mesenchymal
stem cells [17,20]. Our in vitro data showed that human
endothelial cells grown in matrigel induce TEM1/endosia-
lin themselves in response to the culture environment.
Together, the biochemical and localization data support a
functional role for TEM1/endosialin in promoting cell-
cell interactions and migration during tumor angiogen-
esis.
Since the expression profile of TEM1/endosialin and exist-
ent xenograft data suggested TEM1/endosialin might be a
viable therapeutic target for brain tumors, we wished to
ascertain whether TEM1/endosialin  induction was con-
served in an orthotopic model of GBM. Intracranial
U87MG xenografts demonstrated robust upregulation of
Tem1/endosialin in the tumor vasculature with little to no
expression in non-neoplastic brain. Again, staining was
predominantly present in the vessels, although we could
detect staining in occasional tumor stromal cells. Interest-
ingly, when we implanted U87MG cells engineered to sta-
bly overexpress VEGF, a small percentage of tumor cells
stained positive for human TEM1/endosialin, although
there was no significant difference in Tem1/endosialin
staining in the mouse vessels (BNW, unpublished data).
When we implanted intracranial GBM xenografts into
nude Tem1/endosialin KO and WT mice, we detected no
difference in tumor take or survival. This differs from the
colon carcinoma data and suggests that the impact of
Tem1/endosialin in the cerebral microenvironment may
differ from its role in intestinal tumorigenesis. Nanda, et
al., reported a significant decrease in tumor take and vol-
ume when they implanted colon carcinoma xenografts
into the large intestine of nude Tem1/endosialin KO mice
[13]. However, they did not detect a difference in tumor
growth when identical cells were implanted subcutane-
ously into KO and WT animals. They argued that this
emphasized the importance of an anatomically relevant
microenvironment for tumor growth and study. This is a
similar argument to that proposed by Camphausen, et al.,
who compared the expression profiles of U87MG and
U251MG GBM cell lines grown in vitro to those from cellsBMC Cancer 2009, 9:417 http://www.biomedcentral.com/1471-2407/9/417
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grown as subcutaneous or intracranial xenografts [31].
They noted that the expression profiles in tissue culture
were significantly different from the subcutaneous pro-
files, which were, in turn, distinct from the intracranial
expression profiles. The disparity between GBM xenograft
expression profiles suggested that the orthotopic implan-
tation site can dictate gene expression, presumably due to
signaling between the tumor cells and the surrounding
stroma. In the current scenario, it would again appear that
TEM1/endosialin expression levels within distinct anatom-
ical compartments differentially influence tumor growth
and pathology. Importantly, the data suggest that inhibi-
tion of TEM1/endosialin function alone in tumors is insuf-
ficient for suppression of brain tumor growth.
Despite unchanged tumor growth and equivalent animal
survival between Tem1/endosialin WT and KO animals, we
did detect an increase in the number of microvessels
present in the KO GBM tumors. This strengthens a role for
TEM1/endosialin in the maturation of the tumor neo-vas-
culature [13]. TEM1/endosialin was recently reported to
be upregulated by hypoxia via a HIF-2 pathway in a lim-
ited number of cell lines, although we could detect no
induction in primary human endothelial cells [32]. How-
ever, the brain is a highly vascularized site, and it may be
that the level of oxygenation is sufficient to promote
xenograft growth in the absence of Tem1/endosialin induc-
tion. It is more likely TEM1/endosialin is directly or indi-
rectly required for differentiation or maturation of the
vasculature, as opposed to strict proliferation, and that
lack of TEM1/endosialin protein leads to the overabun-
dance of vessels demonstrated in the knockout mouse
tumors. Further studies are needed to determine if the
increased vascularity of the Tem1/endosialin KO tumors
could render them more sensitive to radiation or chemo-
therapy, by enhancing the delivery of radiosensitizing
oxygen or therapeutic drugs.
Conclusion
The combined tumor data confirm that TEM1/endosialin
contributes to the development of the brain tumor vascu-
lature. Although lack of TEM1/endosialin expression did
not inhibit brain tumor growth in our model, the cell sur-
face bioavailability of TEM1/endosialin and its localiza-
tion to tumor and tumor vasculature components in both
primary and metastatic brain tumors, both diseases with
limited current treatment options, support efforts to target
this protein with alternative approaches, including anti-
body or antibody-cytotoxin based strategies, such as a
recently reported anti-TEM1/endosialin IgG conjugated to
saporin, and other efforts in pre-clinical development
[11,21,33] or as combination therapy.
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